Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Rajesh Karan"'
Autor:
Tanuja Chitnis, Angelo Ghezzi, Kumaran Deiva, Peter Huppke, Brenda Banwell, Lauren Krupp, Emmanuelle Waubant, Jutta Gaertner, Virginia DeLasHeras, Amin Azmon, Rajesh Karan
Publikováno v:
BMJ Neurology Open, Vol 4, Iss 1 (2022)
Background In the PARADIGMS Study, fingolimod demonstrated superior efficacy versus interferon (IFN) β-1a and comparable overall incidence of adverse events but slightly higher rate of serious adverse events in patients with paediatric-onset multipl
Externí odkaz:
https://doaj.org/article/860df43c8cbd41c3b813a5753b7ea96d
Autor:
Rama Sivasubramanian, Gangadhar Sunkara, Rajesh Karan, Wei Zhou, Yiming Zhang, Ramachandra Sangana
Publikováno v:
Clinical pharmacology in drug developmentReferences. 11(7)
The bioequivalence of valsartan 160 mg oral solution compared to suspension was assessed in a single-dose, open-label, randomized, 2-period, 2-way crossover study in 82 healthy adults. The participants were randomly assigned (1:1) to receive a single
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3bd74ddbcb07b1de021f00bb1b0f8f6
https://pubmed.ncbi.nlm.nih.gov/35050548
https://pubmed.ncbi.nlm.nih.gov/35050548
Autor:
Lauren Krupp, Brenda Banwell, Tanuja Chitnis, Kumaran Deiva, Jutta Gaertner, Angelo Ghezzi, Peter Huppke, Emmanuelle Waubant, Virginia DeLasHeras, Amin Azmon, Rajesh Karan
Publikováno v:
BMJ neurology open. 4(1)
BackgroundIn the PARADIGMS Study, fingolimod demonstrated superior efficacy versus interferon (IFN) β-1a and comparable overall incidence of adverse events but slightly higher rate of serious adverse events in patients with paediatric-onset multiple
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bfd8e5e32aa3f994c6afad260a72ad2
https://pubmed.ncbi.nlm.nih.gov/35308898
https://pubmed.ncbi.nlm.nih.gov/35308898
Autor:
Peter Huppke, Annik K-Laflamme, Ying Zhang, Emmanuelle Waubant, Gavin Giovannoni, Brenda Banwell, Jerry S. Wolinsky, Lauren B. Krupp, Benjamin Greenberg, Kevin Rostasy, Kumaran Deiva, Jutta Gärtner, Amit Bar-Or, Wolfgang Brück, Douglas L. Arnold, Angelo Ghezzi, Rajesh Karan, Tanuja Chitnis, Amin Azmon
Publikováno v:
Multiple sclerosis (Houndmills, Basingstoke, England). 27(6)
Background: Reduction in absolute lymphocyte count (ALC) is expected with fingolimod treatment. Objective: To evaluate the effect of fingolimod 0.5 mg versus intramuscular interferon β-1a (30 μg) on ALC and its relationship with infections in paedi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7fbf7014ed12f7af3cb2caea5513d19
https://pubmed.ncbi.nlm.nih.gov/32633694
https://pubmed.ncbi.nlm.nih.gov/32633694
Autor:
Rashid Khan Pathan, Uday Kiran Veldandi, Krishna Duvvuri, Rajesh Karan, Fritjof Reinhardt, Sunil Modali, Nikolaos Scarmeas
Publikováno v:
Current Alzheimer research. 18(4)
Background: Transdermal patches are convenient to use, especially in Rotkreuz ZG Rotkreuz ZG patients with Alzheimer’s disease (AD)-associated dementia. However, various identified risks of errors in administering the patches cannot be disregarded.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81a9aca895b25064872e5d1b15ea6542
https://pubmed.ncbi.nlm.nih.gov/34279198
https://pubmed.ncbi.nlm.nih.gov/34279198
Autor:
Bianca Weinstock-Guttman, John R. Corboy, Myla D. Goldman, Daniel Sienkiewicz, Corey C. Ford, Assess Trial Investigators, Edward Fox, Rajesh Karan, Ying Zhang, Susanne Mientus, Douglas L. Arnold, Amit Bar-Or, Bruce A.C. Cree, Barry A Singer, Nadia Tenenbaum
Publikováno v:
JAMA Neurology. 78:48
Importance Doses of fingolimod lower than 0.5 mg per day were not investigated during the fingolimod clinical development program. Whether lower doses of fingolimod might retain efficacy with fewer safety risks remains unknown. Objective To evaluate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::624d784c57cbe3993f28be974404e3bf
https://doi.org/10.1001/jamaneurol.2020.2950
https://doi.org/10.1001/jamaneurol.2020.2950
Autor:
Dominic Aldington, Philip J Wiffen, Sheena Derry, Christopher Eccleston, R Andrew Moore, Anna Wiksten, Ekkehard Glimm, Rajesh Karan, Samik Banerjee
Publikováno v:
Moore, R A, Derry, S, Wiffen, P J, Banerjee, S, Karan, R, Glimm, E, Wiksten, A, Aldington, D & Eccleston, C 2018, ' Estimating Relative Efficacy in Acute Postoperative Pain : Network Meta-Analysis is Consistent with Indirect Comparison to Placebo Alone ', Pain, vol. 159, no. 11, pp. 2234-2244 . https://doi.org/10.1097/j.pain.0000000000001322
Pain
Pain
Supplemental Digital Content is Available in the Text. There was no significant difference between network meta-analysis and simple placebo comparisons in postoperative pain using 261 trials, 39,753 patients, and 52 drug/dose combinations.
Netwo
Netwo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d3710c197c816c267e41967a3437b16
https://purehost.bath.ac.uk/ws/files/183719805/PAIN_D_18_00299_R1.pdf
https://purehost.bath.ac.uk/ws/files/183719805/PAIN_D_18_00299_R1.pdf
Autor:
Rajesh Karan, Karin Meiser, Jingli Duan, Qi Yin, Gangadhar Sunkara, Harold T. Smith, Jin Chen
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 50:33-43
Objective The efficacy and safety of valsartan/amlodipine combination have been demonstrated for the treatment of hypertension. In China, where the prevalence of hypertension is increasing the pharmacokinetic study of valsartan, amlodipine assumes si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::261de1b8b4a98c90aa410812194f5ac8
https://doi.org/10.5414/cp201601
https://doi.org/10.5414/cp201601
Autor:
Surya Ayalasomayajula, Gangadhar Sunkara, Prafulla Bhad, Rajesh Karan, Selene Leon, Venkateswar Jarugula, Gillies-Jacques Riviere
Publikováno v:
The Journal of Clinical Pharmacology. 51:933-942
The steady-state pharmacokinetic (PK) interaction potential between amlodipine (10 mg), valsartan (320 mg), and hydrochlorothiazide (HCTZ; 25 mg) was evaluated in patients with hypertension in a multicenter, multiple-dose, open-label, 4-cohort, paral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b9c76c0088e9e3db1254a9165e39f79
https://doi.org/10.1177/0091270010376963
https://doi.org/10.1177/0091270010376963
Autor:
William P. Dole, Venkateswar Jarugula, Dan Howard, Suliman Al-Fayoumi, Shuyang Zhang, Michael Bartlett, Pei Hu, Ji Jiang, Ching-Ming Yeh, Jianyan Zhang, Rajesh Karan
Publikováno v:
Clinical Drug Investigation. 30:221-228
Background: Aliskiren is the first oral direct renin inhibitor to be approved for the treatment of hypertension. The pharmacokinetic and pharmacodynamic profile of aliskiren has been extensively characterized in Caucasian individuals; however, drug d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3671af30bd4a314bfabb0403b9f23453
https://doi.org/10.2165/11533050-000000000-00000
https://doi.org/10.2165/11533050-000000000-00000